U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07229586) titled 'A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors' on Nov. 13.
Brief Summary: This study aims to evaluate the safety and preliminary efficacy of SHR-7367 in combination with antineoplastic agents in subjects with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Intervention:
DRUG: SHR-7367 Injection
SHR-7367 injection.
DRUG: SHR-1316 Injection
SHR-1316 injection.
DRUG: Paclitaxel for Injection
Paclitaxel for injection (Albumin Bound).
DRUG: Gemcitabine Hyd...